Journal of Psychiatric Research
October 1, 2024
Zixun Wang, Xinyu Hu, Zhongyi Wang et al.
9 citations
Each year, 3-4% of the global population experiences post-traumatic stress disorder (PTSD), a chronic mental disorder with significant social and economic repercussions. Although it has been shown that ketamine can effectively alleviate PTSD symptoms in individuals, the specific mechanism of action underlying its anti-PTSD effects remains unclear. In this study, we investigated how a single,...
The International Journal of Neuropsychopharmacology
October 1, 2024
Gargi Mandal, Madeline Kirkpatrick, Silvia Alboni et al.
12 citations
Understanding the precise mechanisms of ketamine is crucial for replicating its rapid antidepressant effects without inducing psychomimetic changes. Here, we explore whether the antidepressant-like effects of ketamine enantiomers are underscored by protection against cytokine-induced reductions in hippocampal neurogenesis and activation of the neurotoxic kynurenine pathway in our...
Middle East Research Journal of Biological Sciences
September 28, 2024
Carlos Henrique Marchiori, Marco Vinícios de Oliveira Santana, Klebert de Paula Malheiros
Psilocybin and psilocin do not cause addiction or dependence, as they do not interact with the dopaminergic reward system. New pharmacological treatment strategies for substance abuse disorders have targeted craving, which is characterized, in a simplified way, by an intense desire to use the substance. Psilocybin is an indole alkaloid of the hallucinogenic tryptamine group whose molecular...
Neuroscience & Biobehavioral Reviews
September 1, 2024
Jesca E. de Jager, Rutger Boesjes, Gijs H J Roelandt et al.
13 citations
Electroconvulsive shocks (ECS) and ketamine are antidepressant treatments with a relatively fast onset of therapeutic effects compared to conventional medication and psychotherapy. While the exact neurobiological mechanisms underlying the antidepressant response of ECS and ketamine are unknown, both interventions are associated with neuroplasticity. Restoration of neuroplasticity may be a...
ACS Omega
August 27, 2024
Marcelo N. Costa, Livia Goto-Silva, Juliana Nascimento et al.
3 citations
Proteomic analysis of human cerebral organoids may reveal how psychedelics regulate biological processes, shedding light on drug-induced changes in the brain. This study elucidates the proteomic alterations induced by lysergic acid diethylamide (LSD) in human cerebral organoids. By employing high-resolution mass spectrometry-based proteomics, we quantitatively analyzed the differential...
Psychopharmacology
July 4, 2024
Magdalena Kolasa, Agnieszka Nikiforuk, Agata Korlatowicz et al.
18 citations
Our study aimed to unravel the unknown mechanisms behind the exceptional efficacy of Psilocybin (PSI) in treating treatment-resistant depression (TRD). Focusing on Wistar-Kyoto (WKY) rats with a TRD phenotype and Wistar (WIS) rats as a normative comparison, we investigated behavioral and neuroplasticity-related responses to PSI, striving to shed light on the distinctive features of its...
Research Square
June 7, 2024
Målin Schmidt, Anne Hoffrichter, Mahnaz Davoudi et al.
5 citations
preprint
Abstract Psilocybin is studied as innovative medication in anxiety, substance abuse and treatment-resistant depression. Animal studies show that psychedelics promote neuronal plasticity by strengthening synaptic responses and protein synthesis. However, the exact molecular and cellular changes induced by psilocybin in the human brain are not known. Here, we treated human cortical neurons...
Cell Death Discovery
May 1, 2024
Yuan Ruan, Ruolan Yuan, Jiaqi He et al.
11 citations
Abstract Depression is highly prevalent globally, however, currently available medications face challenges such as low response rates and short duration of efficacy. Additionally, depression mostly accompany other psychiatric disorders, further progressing to major depressive disorder without long-term effective management. Thus, sustained antidepressant strategies are urgently needed....
Journal of Psychopharmacology
April 28, 2024
Xiangting Zhao, Yingjie Du, Yishan Yao et al.
53 citations
Background: Psilocybin offers new hope for treating mood disorders due to its rapid and sustained antidepressant effects, as standard medications require weeks or months to exert their effects. However, the mechanisms underlying this action of psilocybin have not been identified. Aims: To investigate whether psilocybin has rapid and sustained antidepressant-like effects in mice and investigate...
Expert Opinion on Therapeutic Targets
April 1, 2024
Carlos Arrabal-Gómez, Pedro Serrano-Castro, Jose Andrés Sánchez-Pérez et al.
7 citations
Major Depressive Disorder (MDD) poses a significant challenge to global health, with current treatments often limited by efficacy and onset delays. This study explores the synergistic antidepressant-like effects of an NPY1R agonist and Ketamine, targeting their neurobiological interactions within the ventral hippocampus. Utilizing a preclinical model, this study administered Neuropeptide Y...